ACTICOR BIOTECH has provided an update on its clinical developments evaluating glenzocimab in the treatment of myocardial infarction. LIBERATE: A phase 2b study evaluating glenzocimab in the treatment of myocardial infarction. The randomized, double-blind Phase 2b LIBERATE trial will include more than 212 patients with ST-segment elevation myocardial infarction (STEMI) who will undergo percutaneous coronary intervention (PCI).
The primary objective of the study is to evaluate the safety and efficacy of glenzocimab 1,000 mg compared to placebo in reducing myocardial infarction size 90 days after the event. This study is being conducted in collaboration with the University of Birmingham (UK), with clinical experts from the Institute of Cardiovascular Sciences and University Hospitals Birmingham NHS Foundation Trust. The two main clinical research sites, Queen Elizabeth Hospital in Birmingham and Northern General Hospital in Sheffield, have been actively recruiting patients since January 2024.
To date, 27 patients have been recruited and study results are expected in the fourth quarter of 2026. GLORIA: A phase 2 study evaluating glenzocimab in the treatment of myocardial infarction. A new phase 2 GLORIA, randomized, double-blind study is being prepared to evaluate glenzocimab in the treatment of myocardial infarction.
The study will enroll approximately 300 patients suffering from STEMI upon emergency admission to cardiac intensive care units. The primary objective of the study is also to evaluate the efficacy of glenzocimab for reducing myocardial infarction surface area at day 90 after percutaneous coronary intervention (PCI), as well as safety. The study plans to test different dose levels and optimize the mode of administration to fit the time needed for this emergency procedure.
The objective of the launch of this second study, which could be promoted by the Company, is to provide all the clinical and regulatory elements necessary for a phase 3 registration as early as 2027, while evolving the method of administration of the product to facilitate the next phase of development and, subsequently, adoption by doctors. Patient recruitment could begin in the first quarter of 2025, provided the Company obtains funding or the project proceeds under receivership.
Acticor Biotech’s LIBERATE Trial: A Promising Study for Myocardial Infarction Treatment, Despite Recent Setbacks
As a renowned blog news writer, I have been following the developments of Acticor Biotech, a company that has been making waves in the biotech industry with its innovative treatments. The latest update on their clinical developments evaluating glenzocimab in the treatment of myocardial infarction has caught my attention, and I would like to provide my analysis of this news article.
According to the article, Acticor Biotech has announced the LIBERATE trial, a phase 2b study evaluating glenzocimab in the treatment of myocardial infarction. This randomized, double-blind trial will include over 212 patients with ST-segment elevation myocardial infarction (STEMI) who will undergo percutaneous coronary intervention (PCI). This development is significant, as it brings hope to patients suffering from STEMI, a severe form of heart attack.
The LIBERATE trial has generated excitement in the medical community, with the UK regulatory agency (MHRA) approving the protocol of the study [[3]]. This approval is a testament to the rigor and potential of the trial. Moreover, the University of Birmingham and Acticor Biotech have announced the full regulatory approval of the LIBERATE clinical study, demonstrating the collaboration and dedication to advancing medical research [[1]].
However, my enthusiasm for the LIBERATE trial is tempered by the recent news that Acticor Biotech has halted a separate phase 2/3 study of a blood thinner given alongside heart surgery due to futility [[2]]. This setback raises concerns about the efficacy of Acticor Biotech’s treatments. Nevertheless, it is essential to recognize that the LIBERATE trial is a distinct study with a different treatment and objective.
In my analysis, the LIBERATE trial represents a promising opportunity for Acticor Biotech to prove the efficacy of glenzocimab in treating myocardial infarction. While the recent halt of another study is a concern, it is crucial to evaluate each study independently. I will continue to monitor the progress of the LIBERATE trial and provide updates on any significant developments.
the LIBERATE trial is an encouraging advancement in the treatment of myocardial infarction, and I look forward to seeing the results of this study. Despite the recent setback, Acticor Biotech’s commitment to medical research and innovation is commendable, and I am eager to see how this trial unfolds.
References:
